Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Carparts.Com Inc (PRTS) Price & Performance

Bristol-Myers Squibb CoTrade
Carparts.Com IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Carparts.Com Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.56 (market cap $116.30B), while Carparts.Com Inc trades at $5.75 (market cap $47.74M). The key difference: Bristol-Myers Squibb Co is far larger — about 2436.1× Carparts.Com Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Carparts.Com Inc pays none. Which is the better fit depends on your goals.

BMYPRTS
Market Cap
$116.30B$47.74M
Sector
HealthConsumer Cyclical
52-Week High
$62.37$11.40
52-Week Low
$42.60$3.88
Enterprise Value
$152.24B$62.71M
Dividend Yield
4.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Carparts.Com Inc

CarParts.com (PRTS) trades at $5.66, down 3.58% today, with a bearish technical signal despite recent positive developments including Nasdaq compliance and a $25 million credit facility. The company shows improving operational metrics with three consecutive earnings beats, though it remains unprofitable with negative margins and cash flow. Valuation metrics appear attractive with P/S of 0.07 and P/B of 0.77, but fundamental challenges persist.

While analyst sentiment is positive (60% buy ratings) and recent corporate actions provide stability, PRTS faces significant execution risks amid declining revenue and persistent losses. The stock offers speculative appeal for turnaround investors but requires careful monitoring of cash burn and profitability improvements. Near-term catalysts include Q2 2026 earnings results expected at -$0.85 EPS.

Returns comparison

Trailing returns across standard periods

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Carparts.Com Inc

CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.

Read more on PRTS